NCT01985971已完成不适用
F18 EF5 PET/CT Imaging in Patients With Brain Metastases From Breast Cancer
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 2
- 试验地点
- 2
- 主要终点
- Number of Participants With Adverse Events
研究概览
简要总结
To estimate the presence of hypoxia in individual lesions after radiotherapy in patients with brain metastases from breast cancer as identified by F18 EF5 PET/CT imaging.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects with measurable brain metastases of at least 1 cm in any plane based on anatomic imaging.
- •Subjects with prior resection of brain metastases with progressions on brain MRI.
- •Histologic confirmation of breast cancer.
- •Age of study subject must be > 18 years.
- •ECOG Performance Status ≤
- •Ability to undergo brain MR and PET imaging
- •Study subjects must have normal organ and marrow function as defined below:
- •WBC >2,000/mmᶟ, platelets >90,000/mmᶟ, total bilirubin <2.0 mg/dl, creatinine <2.0 mg/dl.
- •The effects of EF5 on the developing human fetus are unknown. For this reason, women of childbearing potential must agree to use adequate contraception (hormonal or barrier method of birth control) prior to study entry and for the duration of study participation (1 month). Should a woman become pregnant pr suspect she is pregnant while participating in this study, she should inform her treating physician immediately. Women of childbearing potential will have a urine pregnancy test the day of the F18 -EF5 PET scan prior to the F18 -EF5 injection.
- •Ability to understand, participate and provide a documented signed informed consent.
- •Subjects who are allergic to gadolinium will have MRI scans without gadolinium contrast.
排除标准
- •History of allergic reactions attributed to Flagyl (metronidazole), which has a chemical structure similar to EF
- •Pregnant women are excluded because EF5 has an unknown risk for adverse events in fetuses and nursing infants secondary the administration of EF5 to the mother. Breastfeeding should be discontinued if EF5 is administered to the mother.
- •Subject has any other condition or personal circumstance that, in the judgement of the investigator, might interfere with the collection of complete good quality data.
- •Subjects who are unable to provide informed consent.
- •Patients with prior whole brain radiotherapy.
- •Patients with moderate to severe renal failure, defined as estimated GFR less than 30 ml/Lmin 1.73m²
结局指标
主要结局
Number of Participants With Adverse Events
时间窗: 2 year
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
终止
不适用
Imaging Tumor Hypoxia With 18F-EF5 PET in Recurrent or Metastatic Clear Cell Ovarian CancerOvarian NeoplasmsOvarian CancerNCT01881451British Columbia Cancer Agency5
已完成
2 期
HYPONCO - Hypoxia in Brain TumorsAnaplastic GliomaNCT01200134University Hospital, Caen39
已完成
不适用
A Comparison of MRI Perfusion and FDG PET/CT to Distinguish Between Radiation Injury and Tumor ProgressionBrain CancerNCT01604512Memorial Sloan Kettering Cancer Center148
终止
不适用
EF5 to Evaluate Tumor Hypoxia in Patients With High-Grade Soft Tissue Sarcoma or Mouth CancerStage I Adult Soft Tissue SarcomaStage I Squamous Cell Carcinoma of the Lip and Oral CavityStage II Adult Soft Tissue SarcomaStage II Squamous Cell Carcinoma of the Lip and Oral CavityStage III Adult Soft Tissue SarcomaStage III Squamous Cell Carcinoma of the Lip and Oral CavityNCT00896961National Cancer Institute (NCI)120
已完成
不适用
Assessment of tumor hypoxia during radiotherapy course in locally advanced Head and Neck cancer with 18F-fluoroazomycin arabinoside (18F-FAZA)-PET-CThoofd hals kankerHypoxia in locally advanced Head and Neck cancer10027656NL-OMON36574niversitair Medisch Centrum Groningen20